<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835015</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-074</org_study_id>
    <nct_id>NCT01835015</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration</brief_title>
  <official_title>A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics
      of CLG561 in subjects with advanced age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were divided into 5 cohorts, with the subjects in each cohort being administered a
      single IVT dose of CLG561 in 1 of 5 concentration levels A-E, where A=lowest and E=highest.
      All subjects received active CLG561. Progress from one cohort to the next was time-lagged to
      allow for safety review. Dosing was also time-lagged within each cohort. Only one eye
      (designated as the study eye) was dosed per subject. Post-dose safety assessments and ocular
      examination occurred immediately after the IVT injection and continued throughout the
      outpatient visits at pre-determined timepoints. Collection of post-injection blood samples
      began after the IVT injection at pre-determined timepoints. Subjects were followed for up to
      84 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye</measure>
    <time_frame>Baseline, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>BCVA (with spectacles or other visual corrective devices) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing was reported in letters read correctly. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. One eye (study eye) contributed to the analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Intra-Ocular Pressure (IOP) by Visit - Study Eye</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>IOP was measured by Goldmann applanation tonometry or tonopen, at the discretion of the Investigator, and reported in mmHg (millimeters of mercury). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Change From Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment</measure>
    <time_frame>Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>A dilated fundus examination was performed to evaluate the health of the retina, macula, choroid, and optic nerve. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With a Change From Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment</measure>
    <time_frame>Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>A slit-lamp biomicroscopy examination was performed to evaluate the anterior segment of the eye. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve (AUC) From Time Zero to All [AUC(0-all)]</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)]</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Serum Concentration After Drug Administration (Tmax)</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Observed Maximum Serum Concentration Following Drug Administration (Cmax/D)</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)/D]</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time Zero to Time &quot;t&quot; Where t is a Defined Time Point After Administration [AUC(0-t)]</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (TÂ½)</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F)</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Systemic (or Total Body) Clearance From Serum Following Extravascular Administration (CL/F)</measure>
    <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>CLG561, Concentration Level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLG561, Concentration Level B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLG561, Concentration Level C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLG561, Concentration Level D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLG561, Concentration Level E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLG561</intervention_name>
    <description>Administered by intravitreal injection, Day 1</description>
    <arm_group_label>CLG561, Concentration Level A</arm_group_label>
    <arm_group_label>CLG561, Concentration Level B</arm_group_label>
    <arm_group_label>CLG561, Concentration Level C</arm_group_label>
    <arm_group_label>CLG561, Concentration Level D</arm_group_label>
    <arm_group_label>CLG561, Concentration Level E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of age-related macular degeneration in study eye, as specified in protocol.

          -  Poor visual acuity in study eye, as specified in protocol.

          -  Willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to
             study treatment.

          -  Females must be post-menopausal and/or surgically sterile.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Treatments to the study eye within 28 days prior to study treatment, as specified in
             protocol.

          -  Any disease or medication expected to cause systemic or ocular immunosuppression.

          -  Participation in another interventional clinical study or use of any experimental
             treatment for AMD within 12 weeks prior to study treatment.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Sciences, CA CSI NS/Opth</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>February 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2016</results_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in human</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Serum PK</keyword>
  <keyword>Intravitreal (IVT)</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>Geographic Atrophy</keyword>
  <keyword>Choroidal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 4 investigational centers located in the US.</recruitment_details>
      <pre_assignment_details>Of the 50 enrolled,19 subjects were exited as screen failures prior to randomization. This reporting group includes all assigned subjects (31).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CLG561, Level A</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
        </group>
        <group group_id="P2">
          <title>CLG561, Level B</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
        </group>
        <group group_id="P3">
          <title>CLG561, Level C</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
        </group>
        <group group_id="P4">
          <title>CLG561, Level D</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
        </group>
        <group group_id="P5">
          <title>CLG561, Level E</title>
          <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all enrolled subjects who received CLG561.</population>
      <group_list>
        <group group_id="B1">
          <title>CLG561, Level A</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
        </group>
        <group group_id="B2">
          <title>CLG561, Level B</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
        </group>
        <group group_id="B3">
          <title>CLG561, Level C</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
        </group>
        <group group_id="B4">
          <title>CLG561, Level D</title>
          <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
        </group>
        <group group_id="B5">
          <title>CLG561, Level E</title>
          <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.2" spread="6.82"/>
                    <measurement group_id="B2" value="76.2" spread="8.80"/>
                    <measurement group_id="B3" value="76.1" spread="6.69"/>
                    <measurement group_id="B4" value="73.3" spread="9.52"/>
                    <measurement group_id="B5" value="76.5" spread="10.86"/>
                    <measurement group_id="B6" value="75.3" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Diagnosis</title>
          <description>Geographic atrophy was classified as atrophic lesions in the macula related to AMD as assessed by Fundus autofluorescence. Exudative (wet) macular degeneration was classified as patients suffering from neovascular (wet) AMD, as assessed by fluorescein angiography, who were not likely to require anti-VEGF (vascular endothelial growth factor) therapy during the study period.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Geographic atrophy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exudative macular degeneration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye</title>
        <description>BCVA (with spectacles or other visual corrective devices) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing was reported in letters read correctly. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. One eye (study eye) contributed to the analysis.</description>
        <time_frame>Baseline, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all enrolled subjects who received investigational product. Here, &quot;n&quot; is the number of subjects with non-missing values at the specific time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye</title>
          <description>BCVA (with spectacles or other visual corrective devices) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing was reported in letters read correctly. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. One eye (study eye) contributed to the analysis.</description>
          <population>This analysis population includes all enrolled subjects who received investigational product. Here, &quot;n&quot; is the number of subjects with non-missing values at the specific time point for each arm group, respectively.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=6,6,7,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="16.55"/>
                    <measurement group_id="O2" value="25.7" spread="15.20"/>
                    <measurement group_id="O3" value="27.6" spread="17.67"/>
                    <measurement group_id="O4" value="41.5" spread="20.42"/>
                    <measurement group_id="O5" value="38.0" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline, Day 2, n=6,6,7,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="8.24"/>
                    <measurement group_id="O2" value="2.5" spread="5.24"/>
                    <measurement group_id="O3" value="1.1" spread="3.02"/>
                    <measurement group_id="O4" value="0.0" spread="5.73"/>
                    <measurement group_id="O5" value="-1.0" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline, Day 4, n=6,6,7,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="8.53"/>
                    <measurement group_id="O2" value="4.8" spread="4.67"/>
                    <measurement group_id="O3" value="1.7" spread="3.04"/>
                    <measurement group_id="O4" value="1.8" spread="5.19"/>
                    <measurement group_id="O5" value="3.3" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline, Day 15, n=6,6,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.99"/>
                    <measurement group_id="O2" value="3.7" spread="4.50"/>
                    <measurement group_id="O3" value="2.0" spread="4.73"/>
                    <measurement group_id="O4" value="3.5" spread="8.26"/>
                    <measurement group_id="O5" value="5.2" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline, Day 29, n=6,5,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.85"/>
                    <measurement group_id="O2" value="4.8" spread="5.02"/>
                    <measurement group_id="O3" value="1.3" spread="5.28"/>
                    <measurement group_id="O4" value="2.0" spread="6.84"/>
                    <measurement group_id="O5" value="1.5" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline, Day 57, n=6,5,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="11.09"/>
                    <measurement group_id="O2" value="2.0" spread="3.24"/>
                    <measurement group_id="O3" value="2.5" spread="5.75"/>
                    <measurement group_id="O4" value="4.2" spread="11.09"/>
                    <measurement group_id="O5" value="2.3" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline, Day 85, n=6,6,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="9.43"/>
                    <measurement group_id="O2" value="3.0" spread="4.86"/>
                    <measurement group_id="O3" value="2.2" spread="5.12"/>
                    <measurement group_id="O4" value="2.2" spread="5.12"/>
                    <measurement group_id="O5" value="3.2" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Intra-Ocular Pressure (IOP) by Visit - Study Eye</title>
        <description>IOP was measured by Goldmann applanation tonometry or tonopen, at the discretion of the Investigator, and reported in mmHg (millimeters of mercury). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.</description>
        <time_frame>Baseline, Day 1, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all enrolled subjects who received investigational product. Here, &quot;n&quot; is the number of subjects with non-missing values at the specific time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intra-Ocular Pressure (IOP) by Visit - Study Eye</title>
          <description>IOP was measured by Goldmann applanation tonometry or tonopen, at the discretion of the Investigator, and reported in mmHg (millimeters of mercury). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.</description>
          <population>This analysis population includes all enrolled subjects who received investigational product. Here, &quot;n&quot; is the number of subjects with non-missing values at the specific time point for each arm group, respectively.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=6,6,7,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="2.16"/>
                    <measurement group_id="O2" value="14.3" spread="2.42"/>
                    <measurement group_id="O3" value="15.7" spread="3.86"/>
                    <measurement group_id="O4" value="15.2" spread="3.06"/>
                    <measurement group_id="O5" value="16.5" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, n=6,6,7,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="3.72"/>
                    <measurement group_id="O2" value="20.2" spread="8.01"/>
                    <measurement group_id="O3" value="16.6" spread="6.24"/>
                    <measurement group_id="O4" value="22.3" spread="3.50"/>
                    <measurement group_id="O5" value="20.2" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, n=6,6,7,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="1.79"/>
                    <measurement group_id="O2" value="14.5" spread="1.05"/>
                    <measurement group_id="O3" value="14.3" spread="3.15"/>
                    <measurement group_id="O4" value="14.0" spread="4.00"/>
                    <measurement group_id="O5" value="15.0" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, n=6,6,7,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="2.32"/>
                    <measurement group_id="O2" value="14.5" spread="3.99"/>
                    <measurement group_id="O3" value="15.1" spread="4.74"/>
                    <measurement group_id="O4" value="14.7" spread="4.23"/>
                    <measurement group_id="O5" value="15.3" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, n=6,6,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="1.67"/>
                    <measurement group_id="O2" value="15.5" spread="2.81"/>
                    <measurement group_id="O3" value="16.2" spread="6.21"/>
                    <measurement group_id="O4" value="16.2" spread="3.76"/>
                    <measurement group_id="O5" value="16.5" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, n=6,5,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="3.19"/>
                    <measurement group_id="O2" value="16.8" spread="4.60"/>
                    <measurement group_id="O3" value="16.0" spread="4.94"/>
                    <measurement group_id="O4" value="16.8" spread="4.26"/>
                    <measurement group_id="O5" value="16.2" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57, n=6,5,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="2.94"/>
                    <measurement group_id="O2" value="15.6" spread="5.32"/>
                    <measurement group_id="O3" value="16.3" spread="3.27"/>
                    <measurement group_id="O4" value="16.3" spread="2.25"/>
                    <measurement group_id="O5" value="15.8" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85, n=6,6,6,6,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="2.07"/>
                    <measurement group_id="O2" value="15.5" spread="5.24"/>
                    <measurement group_id="O3" value="16.7" spread="4.27"/>
                    <measurement group_id="O4" value="16.2" spread="4.07"/>
                    <measurement group_id="O5" value="16.2" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Change From Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment</title>
        <description>A dilated fundus examination was performed to evaluate the health of the retina, macula, choroid, and optic nerve. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.</description>
        <time_frame>Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all enrolled subjects who received investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Change From Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment</title>
          <description>A dilated fundus examination was performed to evaluate the health of the retina, macula, choroid, and optic nerve. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.</description>
          <population>This analysis population includes all enrolled subjects who received investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Retina: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retina: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macula: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macula: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choroid: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choroid: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optic Nerve: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optic Nerve: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Change From Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment</title>
        <description>A slit-lamp biomicroscopy examination was performed to evaluate the anterior segment of the eye. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.</description>
        <time_frame>Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all enrolled subjects who received investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Change From Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment</title>
          <description>A slit-lamp biomicroscopy examination was performed to evaluate the anterior segment of the eye. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.</description>
          <population>This analysis population includes all enrolled subjects who received investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lids/Lashes: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lids/Lashes: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cornea: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cornea: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iris: Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iris: Change from Normal to Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve (AUC) From Time Zero to All [AUC(0-all)]</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve (AUC) From Time Zero to All [AUC(0-all)]</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.</description>
          <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="238000" spread="81800"/>
                    <measurement group_id="O5" value="373000" spread="160000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)]</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)]</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
          <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="195000" spread="78300"/>
                    <measurement group_id="O5" value="304000" spread="148000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Serum Concentration After Drug Administration (Tmax)</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Serum Concentration After Drug Administration (Tmax)</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
          <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="144" spread="62.7"/>
                    <measurement group_id="O5" value="187" spread="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Observed Maximum Serum Concentration Following Drug Administration (Cmax/D)</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Observed Maximum Serum Concentration Following Drug Administration (Cmax/D)</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
          <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
          <units>ng/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="102" spread="30"/>
                    <measurement group_id="O5" value="75.8" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-normalized Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)/D]</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)/D]</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.</description>
          <population>This analysis population includes all subjects who received investigational product, completed at least 1 post-injection study visit and for whom serum concentration-time data is available, provided no collection or analytical deviations which would affect the integrity of the data occurred.</population>
          <units>hr*ng/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="38900" spread="15700"/>
                    <measurement group_id="O5" value="30400" spread="14800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve From Time Zero to Time &quot;t&quot; Where t is a Defined Time Point After Administration [AUC(0-t)]</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time Zero to Time &quot;t&quot; Where t is a Defined Time Point After Administration [AUC(0-t)]</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
          <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (TÂ½)</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (TÂ½)</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
          <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F)</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F)</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
          <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Systemic (or Total Body) Clearance From Serum Following Extravascular Administration (CL/F)</title>
        <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
        <time_frame>Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
        <group_list>
          <group group_id="O1">
            <title>CLG561, Level A</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level A</description>
          </group>
          <group group_id="O2">
            <title>CLG561, Level B</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level B</description>
          </group>
          <group group_id="O3">
            <title>CLG561, Level C</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level C</description>
          </group>
          <group group_id="O4">
            <title>CLG561, Level D</title>
            <description>Single 50 Î¼L intravitreal injection of CLG561, Dose Level D</description>
          </group>
          <group group_id="O5">
            <title>CLG561, Level E</title>
            <description>Single 100 Î¼L intravitreal injection of CLG561, Dose Level E</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Systemic (or Total Body) Clearance From Serum Following Extravascular Administration (CL/F)</title>
          <description>Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.</description>
          <population>This parameter was not calculated as AUClast and AUCall were considered sufficient to characterize the systemic exposure to CLG561.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the duration of a subjectâs participation in the study (up to 84 days). Ocular AEs are presented for both study eye and non-study eye. AEs were obtained as solicited comments and observations by the Investigator.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a subject exposed to study drug or any unfavorable and unintended sign, symptom, or disease temporally associated with use of study drug, or untoward medical occurrence at any time prior to administration of first dose of study drug. AEs were reported as pre-treatment and treatment-emergent.</desc>
      <group_list>
        <group group_id="E1">
          <title>CLG561, Level A</title>
          <description>Reported subsequent to the initiation of treatment</description>
        </group>
        <group group_id="E2">
          <title>CLG561, Level B</title>
          <description>Reported subsequent to the initiation of treatment</description>
        </group>
        <group group_id="E3">
          <title>CLG561, Level C</title>
          <description>Reported subsequent to the initiation of treatment</description>
        </group>
        <group group_id="E4">
          <title>CLG561, Level D</title>
          <description>Reported subsequent to the initiation of treatment</description>
        </group>
        <group group_id="E5">
          <title>CLG561, Level E</title>
          <description>Reported subsequent to the initiation of treatment</description>
        </group>
        <group group_id="E6">
          <title>Pretreatment</title>
          <description>Reported prior to the initiation of study treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness Transient</sub_title>
                <description>Study Eye.Transient blindness was due to transient rise in intraocular pressure. Visual acuity returned to pre-injection levels after a paracentesis was performed.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Arcus lipoides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Conjunctivochalasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eyelid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eyelid margin crusting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lacrimal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Optic atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Optic disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vitreal cells</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vitreous degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vitreous opacities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Crystal urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutis laxa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Translational Medicine Expert, Ophthalmology</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

